Edmonton-based Future Fields said Tuesday it closed the oversubscribed round co-led by Amplify Capital, Business Development Bank of Canada’s Climate Tech Fund, and R7 Partners. Existing investors Toyota Ventures, BoxOne Ventures and Builders VC joined the round, with new funders Trac VC and University of Alberta Innovation Fund participating too. Partners from each of this series’ lead investors will also join the board. (The Logic)

Talking point: The startup’s main product is the EntoEngine biomanufacturing platform, which it says is the first synthetic biology system that creates proteins crucial for developing biopharmaceuticals and medicine using fruit flies. Future Fields said that the “status quo approach to [making proteins] was failing supply industry demands,” and geopolitical tensions are “increasing the need for domestic suppliers of these critical materials.” It started its first commercial facility to scale production in December 2024, and has raised US$28 million to date. Future Fields will use the funding to grow its operations and create more bioproducts and medicines.